Evidence map›Paper›PMID 41552672›Full record

ArticleIJTLD open2026

Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and success.

I Maman Lawan, T Decroo, M B Souleymane, A Soumana, C L Aboubacar, A Gagara, R Hamissou Moussa, A A Kabirou Amoussa, I Hamidou, S Hamidou Moussa and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

I Maman LawanDamien Foundation, Niamey, Niger.
T DecrooInstitute of Tropical Medicine, TB-HIV Unit, Antwerp, Belgium.
M B SouleymaneDamien Foundation, Niamey, Niger.
A SoumanaNational Tuberculosis Programme, Coordination, Niamey, Niger.
C L AboubacarNational Tuberculosis Programme, Coordination, Niamey, Niger.
A GagaraHôpital National Amirou Boubarcar Djallo, Sercive Pneumo-Phtysiologie, Niamey, Niger.
R Hamissou MoussaCentre Hospitalier Régional de Tahoua, CAT, Tahoua, Niger.
A A Kabirou AmoussaCentre Hospitalier Régional de Maradi, CAT, Maradi, Niger.
I HamidouFaculté des Science de la Santé, Université André Salifou de Zinder, Zinder, Niger.
S Hamidou MoussaHôpital National Amirou Boubarcar Djallo, Sercive Pneumo-Phtysiologie, Niamey, Niger.
M AdamouMinistère de la Santé Publique, Direction Générale de la Santé Publique, Niamey, Niger.
E AdehossiFaculté des Science de la Santé, Université Abdou Moumouni de Niamey, Niamey, Niger.
S MamadouFaculté des Science de la Santé, Université Abdou Moumouni de Niamey, Niamey, Niger.
B Catherine de JongInstitute of Tropical Medicine, Unit of Mycobacteriology, Antwerp, Belgium.
L RigoutsInstitute of Tropical Medicine, Unit of Mycobacteriology, Antwerp, Belgium.
N LorentDepartment of Respiratory Diseases, University Hospital Leuven, Leuven, Belgium.
M DoutchiFaculté des Science de la Santé, Université André Salifou de Zinder, Zinder, Niger.
A PiubelloDamien Foundation, Medical Unit, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew rifampicin-resistant TB (RR-TB) studies show pre-treatment outcomes and definitive treatment outcomes (accounting for RR-TB re-treatment). Our Niger countrywide study covered 15 years to show the trend of RR-TB diagnoses, time-to-treatment initiation, and pre-and on-treatment attrition (loss to follow-up or death).

methodsRetrospective study including all Niger RR-TB patients diagnosed between 2008 and 2022.

results872 RR-TB patients were diagnosed, 725 (83.1%) started treatment, and 32 required retreatment. Between 2008 and 2013 (phenotypic testing), 2014 and 2018 (regional molecular testing), and 2019 and 2022 (decentralised molecular testing), the annual average first RR-TB treatment initiations increased from 22 to 50 and 85, and the median time to first RR-TB treatment reduced from 260 to 17 and 11 days, by period. Pre-treatment attrition reduced from 34.1% to 12.8% and 12.6%. On-treatment attrition increased from 8.8% to 13.5% and 19.8%. Overall, 81.7% (

conclusionIn Niger, over 15 years of RR-TB control, pre-treatment attrition reduced over time, reflecting better access to care. Treatment success was high, exceeding global success. However, increasing on-treatment attrition should be addressed by targeting high-risk groups.

Indexed as

rifampicin-resistant TBtreatment attritiontreatment outcomestuberculosis

Identifiers

PMID41552672
PMCPMC12810748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.